Caribou Biosciences

OverviewSuggest Edit

Caribou Biosciences is a leading biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. Caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. Forbes Magazine has called Cas9 the protein that "could change biotech forever" and the New York Times has noted that "the pace of new discoveries and applications is dizzying." Caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.

HQBerkeley, CA, US
Employee Ratings3.4

Latest Updates

Employees (est.) (May 2022)100(+4%)
Job Openings26
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Caribou Biosciences

Rachel Haurwitz

Rachel Haurwitz

President and Chief Executive Officer
Barbara McClung

Barbara McClung

Chief Legal Officer and Corporate Secretary
Steven Kanner

Steven Kanner

Chief Scientific Officer
Chris Fuller

Chris Fuller

Vice President of Informatics
Cherry Thomas

Cherry Thomas

Senior Vice President of Clinical Development
Jason O'Byrne

Jason O'Byrne

Chief Financial Officer
Show more

Caribou Biosciences Office Locations

Caribou Biosciences has an office in Berkeley
Berkeley, CA, US (HQ)
2929 Seventh Street
Show all (1)

Caribou Biosciences Financials and Metrics

Summary Metrics

Founding Date


Caribou Biosciences total Funding

$159.5 m

Caribou Biosciences latest funding size

$115 m

Time since last funding

a year ago

Caribou Biosciences investors

Caribou Biosciences's latest funding round in March 2021 was reported to be $115 m. In total, Caribou Biosciences has raised $159.5 m
Show all financial metrics

Caribou Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Caribou Biosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

Caribou Biosciences Online and Social Media Presence

Embed Graph

Caribou Biosciences News and Updates

Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells

-- Data presented at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) -- -- Data presented at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) --

Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy

-- 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) achieved following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- -- CB-010 is the 1st allogeneic CAR-T cell therapy to achieve 100% ORR (5 of 5 patients) --

Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates

-- Initial ANTLER Phase 1 clinical data scheduled to be shared at the European Hematology Association (EHA) 2022 Hybrid Congress for CB-010, the Company’s lead allogeneic cell therapy candidate, in patients with r/r B-NHL -- -- Submission of IND application planned in H2 2022 for CB-011, Caribou’s s…

Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)

-- Data highlight the mechanism underlying the superior specificity of Caribou’s chRDNA genome-editing technology in primary human T cells -- -- Data highlight the mechanism underlying the superior specificity of Caribou’s chRDNA genome-editing technology in primary human T cells --

Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting

-- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- -- Data support an expected Investigational New Drug (IND) application submission in 2022 for CB-011, Caribou’s second allogeneic…

Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL -- -- 2022 submission of IND application planned for CB-011, an allogeneic cell therapy candidate for patients with r/r mul…
Show more

Caribou Biosciences Frequently Asked Questions

  • When was Caribou Biosciences founded?

    Caribou Biosciences was founded in 2011.

  • Who are Caribou Biosciences key executives?

    Caribou Biosciences's key executives are Rachel Haurwitz, Barbara McClung and Steven Kanner.

  • How many employees does Caribou Biosciences have?

    Caribou Biosciences has 100 employees.

  • Who are Caribou Biosciences competitors?

    Competitors of Caribou Biosciences include Biocytogen, TriArm Therapeutics and Tierra Biosciences.

  • Where is Caribou Biosciences headquarters?

    Caribou Biosciences headquarters is located at 2929 Seventh Street, Berkeley.

  • Where are Caribou Biosciences offices?

    Caribou Biosciences has an office in Berkeley.

  • How many offices does Caribou Biosciences have?

    Caribou Biosciences has 1 office.